Qureight Revolutionizes Clinical Trial Imaging with $8.5M Funding

Qureight, a biotech company based in Cambridge, UK, has secured a whopping $8.5 million in their Series A funding round. Founded in 2018, Qureight is on a mission to transform clinical trial imaging analysis and data curation for lung and heart diseases. These diseases, like Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension, are tough nuts to crack with limited treatment options and grim survival rates. The current system of storing valuable patient data in scattered platforms is a nightmare for researchers, who have to manually sift through it, burning time and money. Qureight steps in as the hero, offering a digital hub that organizes various medical data types for in-depth analysis. With special access to healthcare data from NHS England, Qureight can gather CT scans, biomarkers, and trial endpoints in real-time, streamlining the research process. This structured data not only helps identify drug responses and new endpoints but also enables the creation of virtual trial patients for AI modeling. By optimizing clinical trials, enhancing treatments, and developing groundbreaking drugs, Qureight is reshaping the healthcare landscape. Their cloud-based platform is top-notch in terms of data security and compliance, ensuring patient privacy and regulatory standards are met. Collaborations with industry giants like AstraZeneca and Vicore Pharma speak volumes about Qureight's credibility and potential. Dr. Muhunthan Thillai, the brains behind Qureight, sees the Series A closure as a stepping stone towards broader horizons in disease research. With a stellar board and fresh talent onboard, Qureight is gearing up to make a lasting impact on lung and heart disease patients' lives. Leading the funding round is Hargreave Hale AIM VCT, supported by XTX Ventures, Guinness Ventures, and other key investors. Lucy Bloomfield from Hargreave Hale AIM VCT praises Qureight's AI-driven approach in life sciences, highlighting their commitment to innovation. The addition of industry experts like Dr. Debra Barker, Jenny Winter, and Dr. Simon Walsh to Qureight's board signifies a strategic move towards excellence in healthcare. The influx of funds will fuel Qureight's expansion into new disease areas, including lung cancer, propelling them towards groundbreaking discoveries in the medical realm.